Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-cash Items (2019 - 2022)

Nurix Therapeutics (NRIX) has disclosed Non-cash Items for 4 consecutive years, with $85.9 million as the latest value for Q3 2022.

  • Quarterly Non-cash Items rose 56.47% to $85.9 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $85.9 million through Aug 2022, up 56.47% year-over-year, with the annual reading at $2.8 million for FY2021, 98.0% down from the prior year.
  • Non-cash Items for Q3 2022 was $85.9 million at Nurix Therapeutics, up from $68.2 million in the prior quarter.
  • The five-year high for Non-cash Items was $141.2 million in Q4 2020, with the low at $762000.0 in Q4 2019.
  • Average Non-cash Items over 4 years is $60.3 million, with a median of $60.3 million recorded in 2021.
  • The sharpest move saw Non-cash Items skyrocketed 18436.61% in 2020, then tumbled 53.49% in 2021.
  • Over 4 years, Non-cash Items stood at $762000.0 in 2019, then surged by 18436.61% to $141.2 million in 2020, then crashed by 53.49% to $65.7 million in 2021, then soared by 30.76% to $85.9 million in 2022.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $85.9 million, $68.2 million, and $75.2 million for Q3 2022, Q2 2022, and Q1 2022 respectively.